| You are here: Home: BCU 3|2004: John F R Robertson, MD, FRCS: Select publications
Select publications
Ebeling FG et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86(8):1217-22. Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Nicolini A et al. “Tumour marker guided” salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study. Biomed Pharmacother 2003;57(10):452-9. Abstract
Osborne CK et al. J Clin Oncol Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. 2002;20(16):3386-95. Abstract
Robertson JFR et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc ASCO 2003;Abstract 23.
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Robertson JF et al. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 2002;13(Suppl 5):46;Abstract 1640.
|
